Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2026)

Solid Biosciences (SLDB) has 9 years of Cash from Financing Activities data on file, last reported at $239.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 25.98% year-over-year to $239.0 million; the trailing twelve-month figure through Mar 2026 stood at $243.7 million (up 18.94% YoY), and the FY2025 full-year result was $194.4 million, up 58.81% from the prior year.
• Cash from Financing Activities climbed to $239.0 million in Q1 2026, from $5.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $239.0 million in Q1 2026 to a low of -$1.6 million in Q2 2025.
• A 5-year average of $45.1 million and a median of $4.1 million in 2024 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 113137.88% in 2022, while the deepest fall reached 133.33% in 2022.
• Tracing SLDB's Cash from Financing Activities over 5 years: stood at $74.7 million in 2022, then sank by 99.32% to $505000.0 in 2023, then surged by 1274.26% to $6.9 million in 2024, then retreated by 25.89% to $5.1 million in 2025, then soared by 4547.62% to $239.0 million in 2026.
• Business Quant data shows SLDB's Cash from Financing Activities at $239.0 million in Q1 2026, $5.1 million in Q4 2025, and $1.2 million in Q3 2025.